Kovacin is 77.8% effective and resistant to delta variants; Bharat Biotech publishes the results of the third phase tests

New Delhi: Bharat Biotech’s Kovacin vaccine is 77.8% effective. This was evident in the third phase of the clinical trials.

Also read: Closeness with the prisoner; Perforated uniform pants for sex; Bribery of the telephone for keeping the secret; The female guards arrested

On Friday, Hyderabad-based Bharat Biotech released details of the third phase of testing the vaccine. Consequently, Kovixin was found to be 77.8 percent effective against Kovid-19 with symptoms.

Also Read:  Independence Day Celebrations: Capital ready for Independence Day celebrations; Strong Security in Delhi: How India Celebrates Independence Day 2021 in Malayalam and Red Fort Ceremonies

Explaining the experiment’s findings, Bharat Biotech said that covaxin is 93.4 percent effective in people with severe symptoms.

Additionally, the vaccine was found to be up to 63.6 percent effective against the delta variant B1.617.2. The second highest incidence of the disease in the country was in the case of variant B.1.617.2. Expected side effects are less than 0.5 percent on trial.

Also Read:  Don't use 'miracle drug' for Covid: ICMR

Also read: India ranks second with record vaccinations; The center says that the second wave in the country is not over; Special guide

The experiment was carried out from November 16, 2020 to January 7, 2021. Bharat Biotech said the test was conducted on 25,800 people between the ages of 18 and 98. The third phase of the experiment was carried out at the vaccination centers of some 25 selected hospitals across the country.

Also Read:  Amarinder Singh Meets Amit Shah: Congress in Shock; Amarinder to meet Amit Shah, meet Nadda

Related Articles

Back to top button